Christoffer Clemmensen

Associate Professor, University of Copenhagen || Co-founder and CSO, Ousia Pharma ApS

[Christoffer Clemmensen @ClemmensenC]

Our new paper "GLP-1-directed NMDA receptor antagonism for obesity treatment" is out today in @Nature

https://t.co/XmAbLIZ2FX

We describe the engineering and preclinical development of a new drug candidate that targets NMDA receptors in GLP-1 receptor neurons.

1/8 🧵👇

[Helmholtz Diabetes Center (HDC) @helmholtz_diabc]

New review by Jonas Petersen, @TimoMueller_IDO, @clemmensenc et al.:

“The evolving landscape of obesity pharmacotherapy”

📖 @‌NatRevDrugDis | 🔗 https://t.co/pjHIKyttE3
👉 A timely overview of next-generation #obesity therapies beyond #GLP1.

[Jens Lund @jens_lund]

Grateful for the support @EASOobesity @EASOobesityECN @novonordiskfond - and the opportunity to present data on 1) “anti-obesity” metabolites, 2) problems with the pyruvate tolerance test, and 3) feed efficiency as a driver of obesity from @ClemmensenC and @Z_GerhartHines labs!

[Christoffer Clemmensen @ClemmensenC]

@TheFangGroupUiO @MichaelMindrum @NatRevDrugDisc @TimoMueller_IDO @OdgaardJonas @JohansenVBI Thanks a lot 🙏

[Christoffer Clemmensen @ClemmensenC]

Our Review on the evolving landscape of obesity pharmacotherapy is now online in @NatRevDrugDisc
https://t.co/tuLbSCHl8M

@TimoMueller_IDO @OdgaardJonas @JohansenVBI

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2

This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

[Nature Metabolism @NatMetabolism]

Our editor Revati Dewal (@revadewa3) will be attending this exciting symposium on the neuroendocrine control of energy metabolism in Copenhagen (DE) later this month. See below for more details, and reach out to her if you are attending and would like to chat! @DDEA_Denmark

[Jens Lund @jens_lund]

If you are at #ECO2026 in Istanbul, come see data indicating that differences in feed efficiency might be a main explanation for why inbred 🐭 differ so much in HFD-induced weight gain ⚖️ 2/5

[Nature Metabolism @NatMetabolism]

#Throwback

COMMENT |

@ClemmensenC, @Z_GerhartHines, @Thue_Schwartz, @JuleenRZierath, @Kei__Sakamoto

Shaping the future of cardiometabolic innovation: advances and opportunities

https://t.co/SZWrOUrdKA

[Christoffer Clemmensen @ClemmensenC]

In Nature, @TimoMueller_IDO and colleagues describe a unimolecular conjugate that combines GLP-1R/GIPR co-agonism with pan-PPAR nuclear hormone receptor activation within a single therapeutic scaffold. @OdgaardJonas

https://t.co/dO1PGHTQ9h

[Christoffer Clemmensen @ClemmensenC]

@EricTopol Great to have this summarized - and I realize it’s indirectly there, but would be great with maybe 1-2 additional rows with a) preclinical/clinical evidence and b) robustness of said evidence

[Nature Metabolism @NatMetabolism]

#Throwback

COMMENT |
@ClemmensenC, @Z_GerhartHines, @Thue_Schwartz, @JuleenRZierath, @Kei__Sakamoto

Shaping the future of cardiometabolic innovation: advances and opportunities
https://t.co/SZWrOUrLA8

[Keystone Symposia @KeystoneSymp]

⏰ Deadline Dec 16 (11:59pm MST): Submit short talk & scholarship abstracts for the Gut–Brain Axis meeting. Join an all-star speaker lineup this March in Breckenridge, CO.
https://t.co/2lAT95NhVb

@tunepers #KSGutBrain26 #gutbrainaxis #microbiome #gutsensing

[Tomás Schmauck-Medina @TSchmauck]

DR is the oldest intervention to extend max lifespan, and still the strongest we have for mammals. Yet after a century of research, many key questions remain. In our latest @TheFangGroupUiO paper with 310+ refs in @NatureAging we try to answer this... 🧵🧵
https://t.co/ubybvmvyJ3

[Christoffer Clemmensen @ClemmensenC]

@drjasonfung @nicknorwitz https://t.co/Ygw7ruCIj9

Can send pdf if you dont have access.

[Nature Metabolism @NatMetabolism]

#Throwback

COMMENT |
@ClemmensenC, @Z_GerhartHines, @Thue_Schwartz, @JuleenRZierath, @Kei__Sakamoto

Shaping the future of cardiometabolic innovation: advances and opportunities
https://t.co/SZWrOUrLA8

[Christoffer Clemmensen @ClemmensenC]

@DanielJDrucker @ScienceMagazine GLP-1 also did not make it into the otherwise landmark (and great) review in Nature, 2000

https://t.co/yRixY9Pnai

[Nature Metabolism @NatMetabolism]

#Throwback

COMMENT | @ClemmensenC, @Z_GerhartHines, @Thue_Schwartz, @JuleenRZierath, @Kei__Sakamoto

Shaping the future of cardiometabolic innovation: advances and opportunities

https://t.co/SZWrOUrdKA

[Christoffer Clemmensen @ClemmensenC]

@philippefroguel @NatMetabolism @novonordisk Clarifications:
1) none of the authors are from @novonordisk
2) the abstract never says GLP-1R agonists should work in AD, it notes limited preclinical certainty and explains why clinical testing was warranted. EVOKE provided some of that clarity. Happy to share the full PDF.

[Christoffer Clemmensen @ClemmensenC]

New paper out in Aging Cell! We show how NMDA receptor modulation shapes metabolic control. Using memantine in C. elegans, we uncover effects on stress resilience, lifespan and energy metabolism. Led by @VaidaJuozaityte from @Metabolcenter
Open accees: https://t.co/LYbWRtqEYM

[Christoffer Clemmensen @ClemmensenC]

New review from the lab discussing the therapeutic potential of LEAP2 mimetics as an emerging strategy for treating obesity and related cardiometabolic disorders.
@Metabolcenter

https://t.co/muQlSuoq0V